BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Financial Review

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Profitability

This table compares BioCryst Pharmaceuticals and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Swedish Orphan Biovitrum	20.67%	17.92%	9.30%

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Swedish Orphan Biovitrum”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	2.47	$263.86 million	($1.50)	-5.65
Swedish Orphan Biovitrum	$2.89 billion	5.64	$48.85 million	$2.01	22.74

BioCryst Pharmaceuticals has higher earnings, but lower revenue than Swedish Orphan Biovitrum. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for BioCryst Pharmaceuticals and Swedish Orphan Biovitrum, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1	4	6	0	2.45
Swedish Orphan Biovitrum	0	3	5	0	2.62

BioCryst Pharmaceuticals currently has a consensus target price of $19.44, suggesting a potential upside of 129.57%. Given BioCryst Pharmaceuticals’ higher possible upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than Swedish Orphan Biovitrum.

Institutional & Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.